A collaborative immunohistochemical study of Drp1 and cortactin in the epithelial dysplasia and oral squamous cell carcinoma.

Publisher: BioMed Central Country of Publication: England NLM ID: 101251558 Publication Model: Electronic Cited Medium: Internet ISSN: 1746-1596 (Electronic) Linking ISSN: 17461596 NLM ISO Abbreviation: Diagn Pathol Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2006-

Cortactin*/metabolism ; Cortactin*/analysis ; Mouth Neoplasms*/pathology ; Mouth Neoplasms*/metabolism ; Dynamins*/metabolism ; Dynamins*/analysis ; Biomarkers, Tumor*/analysis ; Biomarkers, Tumor*/metabolism ; Squamous Cell Carcinoma of Head and Neck*/pathology ; Squamous Cell Carcinoma of Head and Neck*/metabolism ; Carcinoma, Squamous Cell*/pathology; Humans ; Immunohistochemistry ; Retrospective Studies ; Male ; Female ; Middle Aged ; Aged ; Adult ; Lymphatic Metastasis

Competing Interests: Declarations. Ethics approval and consent to participate: The current study was approved by the Faculty of Dentistry Ethics Committee, and informed consent was obtained from all participants included in the study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Objectives: Oral squamous cell carcinoma (OSCC) accounts for more than 90% of oral malignancies. The poorly understood molecular and cellular mechanisms underlying the pathogenesis of OSCC remain a subject of paramount importance. For epithelial dysplasia, invasion, and metastasis to occur, tumor cells require energy obtained from the mitochondria and phenotypic cellular changes in the actin cytoskeleton. Dynamin-related protein1 (Drp1) is one of the main mitochondrial proteins regulating the mitochondrial dynamics. Cortactin is an actin-binding protein that promotes the actin polymerization and rearrangement. The interplay between both proteins in OSCC remains elusive. The current study aimed to investigate the immunohistochemical (IHC) expression of Drp1 and cortactin in tissues revealing propagating OSCC cases.
Methods: The retrospective study was carried out on 35 formalin-fixed paraffin sections of nodal metastasizing OSCC cases selected from the Oncology Centre, Faculty of Medicine, Mansoura University archives from 2018 to 2023. Immunohistochemistry for Drp1 and cortactin was done. The immune reactivity of both proteins was evaluated using computer-assisted digital image analysis. Statistical analysis was performed to identify significant differences and correlations between both markers in tissues associated with progressing OSCC cases using Chi-Square, Monte Carlo, One-Way ANOVA, and Spearman tests. The p-value less than 0.05 was considered statistically significant.
Results: Drp1 expression was statistically significant to grades of primary OSCC (p = 0.015), while insignificant to grades of epithelial dysplasia (p = 0.123) and metastatic lymph nodes (LNs) (p = 0.212). Statistically significant differences between dysplastic epithelium & primary tumor, dysplastic epithelium & metastatic LNs, and primary tumor and metastatic LNs were observed (p values were 0.014, 0.001, 0.034, respectively). On the other hand, Cortactin expression revealed no statistically significant differences across the three groups. However, statistically significant differences between dysplastic epithelium & primary tumor, dysplastic epithelium & metastatic LNs, and primary tumor and metastatic LNs were found (p values were 0.014, 0.001, 0.034, respectively). Moreover, the Spearman test presented a strong positive correlation between Drp1 and cortactin expression in the studied cases.
Conclusion: Expressions of both Drp1 and cortactin relatively explain their great role in the propagation and the carcinogenesis of OSCC.
(© 2025. The Author(s).)

Oncogene. 2023 Jan;42(4):278-292. (PMID: 36258022)
Diagn Pathol. 2021 Apr 20;16(1):33. (PMID: 33879222)
F1000Res. 2020 Apr 2;9:229. (PMID: 32399208)
J Cell Physiol. 2022 May;237(5):2387-2403. (PMID: 35342955)
Front Pharmacol. 2022 Apr 20;13:825266. (PMID: 35517828)
Cell Biol Int. 2020 Mar;44(3):821-829. (PMID: 31814213)
Mol Oncol. 2022 Jul;16(13):2585-2606. (PMID: 35313071)
Front Cell Dev Biol. 2022 Mar 09;10:849962. (PMID: 35356277)
Biochem Pharmacol. 2020 Dec;182:114282. (PMID: 33058754)
Eur J Oral Sci. 2023 Apr;131(2):e12925. (PMID: 36790139)
Br J Cancer. 2008 Mar 11;98(5):956-64. (PMID: 18268492)
Am J Cancer Res. 2020 May 01;10(5):1278-1293. (PMID: 32509379)
J Gastroenterol Hepatol. 2020 May;35(5):885-895. (PMID: 31674061)
J Dermatol Sci. 2017 Dec;88(3):298-307. (PMID: 28818497)
Liver Int. 2018 Jul;38(7):1263-1272. (PMID: 29210177)
Cancer Prev Res (Phila). 2011 Aug;4(8):1333-41. (PMID: 21646305)
Oncol Lett. 2014 Jul;8(1):133-138. (PMID: 24959233)
FEBS Open Bio. 2023 Jan;13(1):195-208. (PMID: 36468944)
Front Oncol. 2022 Jul 11;12:914593. (PMID: 35898889)
J Transl Med. 2023 May 18;21(1):328. (PMID: 37198593)
J Oral Pathol Med. 2022 Sep;51(8):702-709. (PMID: 36087273)
Oral Dis. 2021 Nov;27(8):1947-1976. (PMID: 34418233)
Oral Dis. 2019 May;25(4):949-971. (PMID: 29878474)
Signal Transduct Target Ther. 2021 Dec 1;6(1):401. (PMID: 34848680)
Acta Biochim Biophys Sin (Shanghai). 2018 Feb 1;50(2):209-215. (PMID: 29329364)
Mol Biol Cell. 2016 Sep 1;27(17):2662-74. (PMID: 27385336)
ACS Omega. 2023 Nov 17;8(48):45208-45223. (PMID: 38075775)
Int J Oral Sci. 2023 Sep 22;15(1):44. (PMID: 37736748)
Oncogene. 2013 Oct;32(40):4814-24. (PMID: 23128392)
PLoS One. 2015 Mar 30;10(3):e0122308. (PMID: 25822260)
PLoS One. 2014 May 06;9(5):e96801. (PMID: 24802416)
J Exp Clin Cancer Res. 2022 Feb 24;41(1):76. (PMID: 35209954)
Front Oncol. 2018 May 04;8:145. (PMID: 29780748)
Nat Rev Dis Primers. 2020 Nov 26;6(1):92. (PMID: 33243986)
Cancers (Basel). 2022 Mar 10;14(6):. (PMID: 35326584)
J Invest Dermatol. 2015 Oct;135(10):2544-2547. (PMID: 26032958)
Ann Transl Med. 2020 Jul;8(14):902. (PMID: 32793746)
J Cell Biol. 2015 Jan 5;208(1):109-23. (PMID: 25547155)
Trends Cell Biol. 2018 Feb;28(2):79-98. (PMID: 29162307)
Mitochondrion. 2020 May;52:115-124. (PMID: 32169612)
J Oral Biol Craniofac Res. 2020 Oct-Dec;10(4):788-799. (PMID: 33194541)
Oral Oncol. 2020 Dec;111:104937. (PMID: 32750558)
Cell Mol Life Sci. 2021 Apr;78(8):3969-3986. (PMID: 33576841)
Cancer Res. 2006 Aug 15;66(16):8017-25. (PMID: 16912177)
Oral Oncol. 2017 Sep;72:38-47. (PMID: 28797460)
Cancers (Basel). 2022 Nov 22;14(23):. (PMID: 36497206)
Medicine (Baltimore). 2019 Nov;98(48):e18228. (PMID: 31770286)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Oral Oncol. 2012 Jul;48(7):641-6. (PMID: 22377015)
Cancers (Basel). 2020 Jan 18;12(1):. (PMID: 31963677)
J Mol Med (Berl). 2022 Jan;100(1):1-21. (PMID: 34657190)
Am J Pathol. 2020 May;190(5):958-967. (PMID: 32084363)
Head Neck Pathol. 2022 Mar;16(1):54-62. (PMID: 35312982)
J Oral Pathol Med. 2022 Apr;51(4):342-349. (PMID: 35122318)
Cancers (Basel). 2020 Oct 01;12(10):. (PMID: 33019722)
Cancer Metastasis Rev. 2021 Mar;40(1):89-140. (PMID: 33471283)
Oncotarget. 2017 Mar 28;8(13):20543-20557. (PMID: 28423551)

Keywords: Cortactin; Drp1; IHC; OSCC

0 (Cortactin)
0 (CTTN protein, human)
EC 3.6.5.5 (Dynamins)
0 (Biomarkers, Tumor)
EC 3.6.5.5 (DNM1L protein, human)

Date Created: 20250411 Date Completed: 20250412 Latest Revision: 20250413

20250414

PMC11987395

10.1186/s13000-025-01627-0

40217339